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ABSTRACT  
Pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive human 
malignances, is thought to be initiated by KRAS activation. Here we find that 
transcriptional activation mediated by the Gli family of transcription factors, although 
dispensable for pancreatic development, is required for Kras-induced proliferation and 
survival in primary pancreatic epithelial cells in culture, and Kras-driven pancreatic 
intraepithelial neoplasia and PDAC formation in vivo. Further, ectopic Gli1 activation in 
the mouse pancreas accelerates Kras-driven tumor formation, underscoring the 
importance of Gli transcription factors in pancreatic tumorigenesis. Interestingly, we 
demonstrate Gli-stimulated IKBKE (IKK)/nuclear factor-kappaB (NF-B) activity in 
pancreatic cancer cells in culture and in vivo, and show that this activity is a critical 
downstream mediator for Gli-dependent PDAC cell transformation and survival. 
Together, these studies demonstrate for the first time the requirement for Gli in Kras-
dependent pancreatic epithelial transformation, implicate a novel mechanism of Gli-NF-
B oncogenic activation, and provide genetic evidence supporting the therapeutic 
targeting of Gli activity in pancreatic cancer.  
 
 
 
 
\body  
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INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer 
mortality in the United States, with a 5-year survival rate of less than 5% (1, 2). PDAC is 
thought to arise from precursor lesions termed pancreatic intraepithelial neoplasias 
(PanINs), which are characterized by mutations in KRAS  and are believed to be 
initiating events in this cancer (3, 4). The importance of activating KRAS mutations in 
PDAC development is further underscored by studies of mouse models of the disease 
(5-7). Thus, understanding of the molecular and genetic mechanisms in Kras-dependent 
pancreatic tumorigenesis is essential for the development of early diagnostic and 
treatment tools.  
The Gli transcription factors - Gli1, Gli2, and Gli3 - are effectors of the Hedgehog (Hh) 
signaling pathway. In mammalian cells, the Hh ligands bind to the 12-pass 
transmembrane receptor, Patched1 (Ptch1), leading to activation of the seven-pass 
membrane protein, Smoothened (Smo). Smo-mediated intracellular signal transduction 
controls the activity of the Gli proteins, resulting in transcriptional responses in target 
tissues (8-10). Dysregulation of Hh-Gli signaling is likely involved in multiple aspects of 
PDAC formation (11-18); yet its exact roles remain poorly characterized.  Unlike Hh-
related tumors associated with Gorlin syndrome, mutations in cell surface molecules 
such as Ptch and Smo have not been identified in human pancreatic cancers (11, 19-
21). However, Hh ligands are highly expressed in human and mouse PDAC (12, 13, 15, 
18), and emerging evidence suggests that the ligands regulate pancreatic tumor 
development through a paracrine mechanism. In this model, Hh ligands produced by 
epithelial tumor cells signal to the adjacent stroma, thereby altering the tumor  
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microenvironment and regulating tumor growth (16, 17, 22, 23). This model is further 
supported by recent studies demonstrating that neither genetic removal nor activation of 
Smo in the pancreatic epithelium affects Kras-induced pancreatic tumor formation (18, 
23). Consistent with this, treatment of a PDAC mouse model with a Smo antagonist led 
to alterations in the tumor stroma and enhanced tumor response in combination with 
gemcitabine (17).  
Surprisingly, Gli expression within the pancreatic tumor epithelium is maintained despite 
Smo deletion and does not correlate with Hh ligand levels (18), suggesting a more 
complex regulation of the pathway. Several recent studies have also shown that Gli1 
gene expression in PDAC cells is regulated by oncogenic pathways such as Kras and 
transforming growth factor beta (TGF-), independently of Hh ligand input and the 
canonical intracellular pathway through Ptch and Smo (18, 24). Gli1 is also required for 
PDAC cell survival and transformation in culture (18), and ectopic activation of Gli2 in 
the mouse pancreas induces the formation of undifferentiated tumors (14). Interestingly, 
sequencing of human PDAC specimens identified mutations in genes encoding Gli 
transcription factors, including GLI1 and GLI3 (3). Together, these data suggest a cell-
autonomous regulation of Gli activity in pancreatic tumor epithelial cells, independent of 
Hh ligands. However, the requirement for Gli activation within the tumor epithelium has 
not been established in vivo, and the underlying molecular consequences of Gli-
mediated transcription during pancreatic tumorigenesis remain unexplored.  
In this study, we describe the generation of a novel mouse model of epithelium-specific 
inhibition of Gli transcriptional activity in Kras-induced pancreatic cancer. We find that 
although blocking Gli-induced transcription does not affect pancreatic development, it  
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potently inhibits Kras-driven PanIN and PDAC formation.  Conversely, ectopic Gli1 
expression accelerates Kras-mediated pancreatic tumorigenesis. Using gene 
expression profiling and functional assays, we identify downstream regulation of the 
IKBKE/NF-B pathway as a novel mechanistic link between Gli transcriptional activation 
and PDAC cell transformation.  
 
RESULTS 
Gli activity is not required for pancreatic development 
To investigate the role of Gli transcriptional activity in pancreatic development, we used 
a conditional Rosa26 knock-in allele of Gli3T (R26-Gli3T), which allows ectopic 
expression of Gli3T protein from the ubiquitously expressed Rosa26 locus following 
Cre-mediated recombination (25). Gli3T is a C-terminally truncated form of Gli3 that acts 
as a dominant repressor of Gli transcription. Over-expression of Gli3T specifically 
inhibits Gli1- and Gli2-dependent gene transcription, but not lymphoid enhancer-binding 
factor-1 (LEF1) or serum-response-factor (SRF)-mediated gene transcription in cultured 
NIH3T3 cells (Fig. 1A-C). These results show the specificity and effectiveness of the 
Gli3T allele in blocking Hh/Gli transcriptional activation.  
We crossed R26-Gli3T mice to Ptf1a-Cre transgenic mice that direct Cre recombinase 
expression to the epithelial lineages of the mouse pancreas (26). Ptf1a-Cre;R26-Gli3T 
mice were born at the expected frequency, and their pancreata showed normal 
parenchymal architecture and cytodifferentiation up to the age of 12 months, the longest 
time examined (n = 10) (Fig. 1E and J). In the R26-Gli3T allele, a 3XFlag tag and IRES- 
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Venus unit are also inserted at the C-terminus of Gli3T to facilitate identification of 
transgene expression (25).  Therefore, we used detection of the Flag tag with 
immunoblotting (Fig. 1D) and Venus fluorescence on cyrosections (Fig. 1N) to confirm 
Cre-mediated expression of Gli3T in pancreatic tissue from Ptf1a-Cre;R26-Gli3T mice. 
We analyzed the expression of the endocrine markers insulin and glucagon and the 
acinar cell marker amylase, and found no significant differences between Gli3T-
expressing and control pancreata (Fig. 1F, G, H, K, L and M). These data show that 
Gli3T inhibition does not affect differentiation of the pancreatic epithelial lineages, and 
suggest that cell-autonomous Hh-Gli activity is largely dispensable for the proper 
development of mouse pancreas.  
 
Gli activation is required for Kras-induced PanIN lesion formation 
We next investigated the specific role for Gli transcription in regulating Kras-initiated 
tumor development in vivo. We generated a mouse model in which simultaneous 
activation of Kras and inhibition of Gli transcription was achieved by breeding mice 
harboring a conditionally activated Kras allele (LSL-Kras
G12D) (27) with Ptf1a-Cre;R26-
Gli3T mice. As reported previously, Cre-mediated activation of the LSL-Kras
G12D allele 
in the mouse pancreas results in the development of slowly progressive PanINs (5). At 
6 months of age, Ptf1a-Cre;LSL-KRAS
G12D mice developed early PanIN lesions, most of 
which were classified histologically as PanIN1A and PanIN1B (Fig. 2A). These lesions 
showed a high proliferation index, demonstrated by Ki67 immunohistochemistry (IHC), 
and evidence of epithelial transformation with associated mucin accumulation as 
detected by Alcian blue staining (Fig. 2C and E). By 12 months of age, the pancreata of  
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the  Ptf1a-Cre;LSL-Kras
G12D  mice displayed evidence of more advanced lesions, 
including PanIN2 and PanIN3 lesions (Fig. 2G).  
In contrast, inhibition of Gli activity resulted in a dramatic reduction in Kras-driven 
tumorigenesis. Ptf1a-Cre;LSL-Kras
G12D;R26-Gli3T mice (n=15) examined at 6 months 
and 12 months of age showed a largely normal parenchymal architecture in the 
pancreas with little evidence of epithelial transformation (Fig. 2B and 2H). Most of the 
cells in the pancreas were nonproliferating as determined by Ki67 staining, and there 
was no reactive stroma (Fig. 2D and 2F), suggesting a critical requirement for Gli 
transcriptional activation in Kras-induced PanIN lesion formation in vivo.   
Pancreatic ductal epithelial transformation is a critical step in the development of Kras-
initiated PanIN lesions. Thus, we examined the effect of Gli3T expression on Kras-
induced phenotypes in primary pancreatic duct epithelial cells (PDECs) in culture. 
Consistent with our previous work (15), we found that Kras activation induced the 
proliferation of PDECs and enhanced their survival in response to challenge by 
apoptotic stimuli (Fig. S1). However, Gli3T expression abrogated Kras-induced PDEC 
survival after exposure to cycloheximide (Fig. S1A), and also impaired Kras-induced 
proliferation in PDECs (Fig. S1B). Together, our in vivo and in vitro data suggest that Gli 
activation is critical for Kras-initiated pancreatic tumorigenesis, potentially by mediating 
Kras-induced epithelial cell proliferation and survival. 
Interestingly, we did detect a few rare PanIN1 lesions in three Ptf1a-Cre;LSL-
Kras
G12D;R26-Gli3T mice (Fig. 2H and I). This observation suggests the possibility that 
the Gli requirement could eventually be overcome, or that the lesions that developed  
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failed to express Gli3T. To differentiate between these possibilities, we assayed for 
transgene expression in these lesions. Because of the high background in detecting the 
Gli3T C-terminal Flag tag with immunofluorescence staining or IHC, we took advantage 
of the IRES-Venus unit inserted in the R26-Gli3T allele that allows detection of 
transgene expression by Venus fluorescence on cryosections. We found that the 
lesions from Ptf1a-Cre;LSL-Kras
G12D;R26-Gli3T mice were Venus negative compared to 
the adjacent normal-appearing islet and acinar tissues (Fig. 2I and J), indicating that the 
Gli3T transgene was not expressed in these lesions. These results suggest that the 
development of rare lesions in animals bearing the R26-Gli3T allele is probably due to 
inefficient Cre recombination and the failure to express Gli3T. 
 
Gli activation is required for Kras-dependent PDAC formation 
Our data suggest that Gli transcriptional activity is required for Kras-initiated formation 
of precursor PanIN lesions. To test whether Gli activity is required for progression to 
adenocarcinoma, we generated compound mice bearing a single floxed Trp53 allele 
(28) in addition to the LSL-Kras
G12D, R26-Gli3T, and Ptf1a-Cre alleles. Mice negative for 
the R26-Gli3T allele rapidly developed pancreatic carcinomas with a median latency of 
111 days (range 85-164 days) (Fig. 3A). These tumors were predominantly moderately- 
to poorly-differentiated ductal adenocarcinomas that were frequently invasive and 
metastatic, with dissemination to lymph nodes, the adjacent intestine, liver, peritoneal 
cavity and lungs (Fig. 3B, panels i-v).  Non-tumor-bearing pancreatic tissue displayed 
acinar atrophy and contained numerous PanINs from PanIN1 to PanIN3 (Fig. 3B, panel 
I). By contrast, mice bearing the R26-Gli3T allele developed carcinomas with a  
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significantly longer latency, with a median age of 193 days (range 115-270 days), p 
<0.001 by Log-rank test (Fig. 3A). Histologically, the tumors that developed in the R26-
Gli3T-positive animals were indistinguishable from those in R26-Gli3T-negative mice, 
and were also commonly metastatic (Fig. 3B, panels vi-ix). Characterization of tumors 
by immunostaining for Ki67 or the pancreas progenitor marker PDX1, and 
immunoblotting for AKT and ERK phosphorylation, showed no differences between 
tumors induced in R26-Gli3T-positive and -negative animals (Fig. S2).  
Despite the delayed kinetics, the eventual formation of pancreatic tumors in animals 
bearing the R26-Gli3T allele again raises the question whether the tumors that 
developed failed to express Gli3T, or whether Trp53 deletion obviates the need for Gli 
activity, as suggested by a previous study (29). Thus, we assayed for the presence of 
Gli3T protein in lysates from tumors, and cell lines derived from these tumors, by 
immunoblotting with an anti-Flag antibody. While Gli3T protein could be readily detected 
in 293T cells transfected with a Gli3T expression construct (and pancreas tissue from 
Ptf1a-Cre;R26-Gli3T mice, see Fig. 1), Gli3T could not be detected in any of the tumor 
(Fig. 3C, top panel) or cell line (Fig. 3C, lower panel) lysates. To determine whether 
these tumors were derived from cells that failed to undergo recombination, we analyzed 
DNA extracted from tumors and cell lines with PCR primers that differentiate between 
unrecombined and recombined R26-Gli3T alleles. The unrecombined allele was readily 
detected in all samples isolated from mice carrying the R26-Gli3T allele, whereas only 
one tumor sample tested positive for the presence of the recombined allele (Fig. 3D). 
Interestingly, a cell line derived from the tumor that tested positive for recombination 
was negative for the presence of the recombined R26-Gli3T allele, suggesting that the  
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cells in the tumor carrying the recombined allele represented a minority of the sample, 
or were normal epithelial cells entrapped within the mass of the tumor. Collectively, our 
data demonstrate that Gli transcriptional activity is required for pancreatic carcinoma 
development in vivo. 
 
Gli1 accelerates Kras-initiated pancreatic tumorigenesis 
Prior work suggested that Kras regulates Gli1 expression in PDAC cells, and Gli1 
activity is critical for PDAC cell survival and transformation in vitro (18). However, the 
tumorigenic activity of Gli1 has not been examined in the pancreas in vivo. Therefore, 
we used a recently established conditional Rosa26 knock-in allele of Gli1, R26-Gli1 (30, 
31), to ectopically express Gli1 in the mouse pancreas.  
Ptf1a-Cre;R26-Gli1 mice were generated and monitored for over 12 months. Gli1 
activation alone did not initiate pancreatic tumors, and the pancreatic development and 
cytodifferentiation appeared normal in Ptf1a-Cre;R26-Gli1 mice compared to control 
R26-Gli1 mice (Fig. S3). However, activation of both Kras and Gli1 within the pancreas 
dramatically accelerated tumorigenesis. Although the pancreas appeared normal at 
birth, the health of the triple-transgenic Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1 mice 
deteriorated rapidly, and the majority of the animals were sacrificed between 6 and 12 
weeks of age, although few survived to the age of 10 months (Fig. 4A).  At 2 months of 
age, the Ptf1a-Cre;LSL-Kras
G12D mice demonstrated only few early PanIN1 lesions as 
reported previously (5), while the vast majority of the pancreas contained well-organized 
acinar, islet and ductal tissue (Fig. 4C). In contrast, the Ptf1a-Cre;LSL-Kras
G12D;R26-
Gli1 mice had wide-spread formation of PanIN lesions resulting in almost complete  
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disruption of normal pancreatic architecture. These lesions showed a variety of nuclear 
atypia in the ductal epithelium; some corresponding to human PanIN3 lesions (Fig. 4D). 
Cytokeratin 8 (CK8) staining confirmed the epithelial phenotype (Fig. 4E). A prominent 
desmoplastic stromal response, confirmed by smooth muscle actin (SMA) staining, was 
also present (Fig. 4E).  
Molecular analysis of the Kras/Gli1 advanced lesions revealed that cell proliferation as 
measured by Ki67 staining was significantly increased compared to the lesions with 
Kras activation alone (Fig. 4F and G, and Fig. S4A). Consistent with a previous report 
(32), we also detected senescence-associated β-galactosidase expression in early 
PanIN lesions from two-month-old Ptf1a-Cre;LSL-Kras
G12D mice (Fig. 4H), while high-
grade PanIN lesions from age-matched Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1 mice did not 
exhibit detectable senescence-associated β-galactosidase staining (Fig. 4I and Fig. 
S4B), suggesting escape from Kras
G12D-induced growth arrest/senescence.  However, 
we did not detect invasive PDAC in the Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1  mice, and 
metastasis was not observed in any of the mice we examined. Interestingly, we 
detected large multilocular cystic lesions resembling mucinous cystic neoplasms (Fig. 
4J) in two of the Ptf1a-Cre;LSL-KRAS
G12D;R26-Gli1 mice, one at 6 weeks of age and 
the other at 8 months of age, in addition to the PanIN lesions we described above. The 
cysts from the Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1 mice were as large as 2 cm in diameter 
and lined by columnar epithelial cells, where abundant mucin production was 
demonstrated by reaction with Alcian blue (Fig. 4K). Immunohistochemistry for estrogen 
receptor (ER) and progesterone receptor (PR) in these cystic lesions showed the 
presence of ER or PR positive cells in the stroma (Fig. S4C and D), a key feature of  
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human mucinous cystic neoplasms.  Taken together, these results suggest that Gli1 
activation is not sufficient to initiate PDAC, but synergizes with Kras to promote 
pancreatic tumor formation in vivo.  
 
A Gli-dependent transcriptional program in PDAC cells 
The results from our loss-of-function and gain-of-function genetic analyses underscore 
the functional importance of Gli activation in pancreatic ductal epithelial transformation. 
However, the Gli-mediated transcriptional program in pancreatic cancer remains largely 
unexplored.  
Panc1 and MiaPaCa2 are human PDAC cell lines that contain activating mutations in 
Kras and require Gli1 activity for survival and maintenance of their oncogenic properties 
(18). To further examine Gli-mediated transcriptional regulation in these cells, Panc1 or 
MiaPaCa2 cells were transfected with a Gli3T expression vector, infected with shRNA 
constructs against Gli1, or treated with a small molecule Gli inhibitor, GANT61. We 
found that Gli3T effectively blocked Gli-dependent transcriptional activation in the Panc1 
or MiaPaCa2 cells (Fig. 5A), consistent with the result that expression of the Gli target 
genes,  Ptch1 and Gli1, was down-regulated in Ptf1a-Cre;LSL-Kras
G12D;R26-Gli3T 
mouse mutant pancreas (Fig. S5A). In agreement with previous studies(18), we found 
that inhibition of Gli-mediated transcription by expression of Gli3T, shRNAs against Gli1, 
or treatment of GANT61, inhibited cell proliferation, increased apoptosis, and impaired 
anchorage independent growth in these cell lines (Fig. 5B-D, and Fig. S5F-K). Together, 
these data demonstrated the importance of Gli transcriptional activation in human 
PDAC cells.  
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To identify Gli-dependent downstream target genes, we performed gene expression 
profiling on Gli3T-expressing Panc1 cells and vector controls. We transfected Panc1 
cells with a Gli3T-IRES-nuclear GFP expression construct, and 24 hours post-
transfection we isolated GFP-positive cells by FACS and performed expression profiling 
using Affymetrix chips. As expected, we detected upregulation of Gli3 that likely reflects 
the expression of the ectopic Gli3T transgene. We identified 265 genes that were 
significantly downregulated by Gli3T (Table S1); among them, Ptch1 and FoxA2 are 
known transcriptional targets of the Hh-Gli pathway (Fig. 5E). Interestingly, we also 
identified several genes involved in regulating Ras intracellular signal transduction, 
including  SOS2 (RasGEF), RASA1 (RasGAP), RIN2 and RASSF4/5 (Fig. 5E), 
suggesting possible feedback regulation of Kras signaling in cancer cells influenced by 
Gli activity.  
The PI3K/AKT and MEK/ERK pathways are Kras-stimulated signaling pathways that 
have been implicated in tumorigenesis (33). In our transcriptional profiling, we found 
that two subunits of PI3K, PIK3R1 and PIK3C2B, were among the genes whose 
expression was significantly downregulated by Gli3T (Fig. 5E), indicating a possible 
interaction between Gli and PI3K/AKT signaling. Thus, we further examined the status 
of these two critical Kras downstream pathways in PDAC cells.  We found that Akt 
phosphorylation was markedly downregulated in Gli3T-expressing Panc1 cells (Fig. 5F), 
but was elevated in mouse pancreatic tumors with both Kras and Gli1 activation (Fig. 
5G and H). In contrast, ERK phosphorylation was not significantly changed in mouse 
PanIN lesions and human cancer cells upon Gli regulation (Fig. 5F, I and J). These  
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results are in agreement with a previous report that showed activation of AKT, but not 
ERK, when an active form of Gli2 was expressed in mouse pancreas (14).  
Hh-Gli regulates Wnt signaling in several developmental, tissue regeneration and 
tumorigenic contexts  (16, 34-37). Interestingly, a recent study suggested that Wnt 
signaling may also be regulated by Hh signaling in pancreatic tumors (38). Thus, we 
examined the canonical Wnt activity in Panc1 cells where Gli transcription activity was 
inhibited by Gli3T. Quantitative RT-PCR (qPCR) analysis showed that the expression of 
a well-established Wnt target gene AXIN2 was not inhibited by Gli3T expression in 
Panc1 and MiaPaCa2 cells (Fig. S6). This result is consistent with the absence of Wnt 
pathway target genes from the list of differentially expressed genes identified by our 
microarray experiments (Table S1), and the absence of -catenin nuclear accumulation 
in the PanIN lesions with both Kras and Gli1 activation (Fig. S6). These data are also 
consistent with our genetic result that Gli3T expresion did not affect embryonic 
pancreatic development (Fig. 1), where canonical Wnt signaling plays a prominent role 
(39, 40).  Together, these data suggest that regulation of canonical Wnt signaling may 
not play a major role in our Gli-dependent pancreatic tumor models.  
 
Gli-mediated regulation of IKBKE and NF-B activation in pancreatic tumors.  
Our gene expression profile analysis detected an enrichment of genes associated with 
the NF-B pathway, including IKBKE (IKK), TRAF1, TRAF3IP2 and NFKBIE (Fig. 5E). 
IKBKE (IKK) is a IB Kinase (IKK)-related kinase involved in the activation of the NF-
B pathway (41, 42), and was recently identified as a breast cancer oncogene (43).  
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Importantly, elevated IKBKE expression was recently shown to be a common feature of 
PDAC(44). Thus, we examined whether IKBKE/NF-B activation constituted a novel 
downstream mechanism of Gli transcription in pancreatic cancer. 
We first examined whether NF-B transcriptional activity is regulated by Gli-mediated 
transcription. Panc1 cells expressing Gli3T, shRNAS against Gli1, or treated with 
GANT61, exhibited a significantly lower level of NF-B activity compared to cells 
expressing a control plasmid as assayed by measuring the activity of a synthetic NF-B 
reporter gene (Fig. 6A). Inhibition of Gli transcriptional activation in Panc1 cells also 
resulted in marked downregulation of IKBKE gene expression as measured by qPCR or 
immunoblot analysis (Fig. 6B and C). To determine the functional importance of IKBKE 
in PDAC cells, we used two shRNA constructs against human IKBKE to silence IKBKE 
expression in Panc1 or MiaPaCa2 cells, and confirmed knockdown efficiency by qPCR 
(Fig. 6D and Fig. S7A). We found that inhibition of IKBKE expression reduced cell 
numbers, relative to a non-silencing shRNA control, as measured by an MTT assay 
(Fig. 6F and Fig. S7C). Further, IKBKE knockdown increased apoptosis, as illustrated 
by caspase 3 cleavage (Fig. 6G and Fig. S7D), and impaired the ability of PDAC cells to 
form colonies in soft-agar (Fig. 6H and Fig. S7E). Importantly, these phenotypes were 
rescued by co-expression of a mouse IKBKE expression vector that is resistant to the 
two shRNAs targeting human IKBKE (Fig. 6E-H and Fig. S7B-E). Together, these data 
indicate that IKBKE is required for the survival and transformation phenotypes of human 
PDAC cells.   
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Next, we determined whether IKBKE and NF-B activity are regulated by Gli-mediated 
transcription in vivo. RelA is a member of the NF-B family, and nuclear accumulation of 
RelA indicates activation of the classical NF-B pathway. We therefore performed IHC 
for IKBKE and RelA in tissue samples from Ptf1a-Cre;LSL-Kras
G12D and Ptf1a-Cre;LSL-
Kras
G12D;R26-Gli1 mice at the age of 2 months. We found that, compared to those in 
Ptf1a-Cre;LSL-Kras
G12D mice, epithelial cells in Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1 mice 
exhibited significantly increased IKBKE expression and nuclear RelA staining (Fig. 6I-L).  
In summary, these observations demonstrate activation of IKBKE/NF-B signaling by 
Gli proteins in PDAC cells, and highlight a potential mechanism for the observed 
requirement for Gli transcription for PDAC development in vivo. 
 
DISCUSSION 
Non-canonical Gli function in pancreatic tumor cells 
Non-canonical Gli regulation has been reported and implicated in several oncogenic 
settings (29, 45-48).  A growing body of evidence also suggests a cell-autonomous non-
canonical Gli regulation in pancreatic cancer that is distinct from the the Hh ligand-
dependent paracrine effect on the tumor stroma (3, 11, 18, 24, 49). Our results here, 
together with a previous report (14), show that, unlike Smo activation (23), Gli1 or Gli2 
activation is able to cooperate with Kras to promote pancreatic tumorigenesis.   
Moreover,  GLI1 and GLI3 were recently reported to be mutated in human PDAC-
derived cells (3), and the expression of Gli1 and Gli3 can be regulated in Smo-null  
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mouse pancreatic tumor cells (18). Together, these studies support the non-canonical 
model, and indicate a broad involvement of Gli mis-regulation in pancreatic cancer.  
Using a dominant repressor Gli3T allele that inhibits all Gli-mediated transcriptional 
activation, we demonstrate for the first time that Gli transcriptional activity is specifically 
required for pancreatic tumor formation in vivo, although it is dispensable for normal 
pancreatic development.  Importantly, our data show that Gli activity is required not only 
for pancreatic tumor initiation, but also for the maintenance of established PDAC cells.  
Given the demonstrated importance of Hh ligands on the desmoplastic stroma, our 
results suggest that Gli proteins are attractive therapeutic targets(45, 50) in PDAC, as 
their inhibition would affect both the tumor epithelium and the reactive stroma.   
It is currently not well understood why the pancreatic epithelium is refractory to 
Ptch/Smo-mediated canonical signaling or how Kras potentially regulates Gli expression 
levels(18, 49, 51); however, recent work points to an interesting potential connection 
with the primary cilium (52). Significant Gli signal up-regulation was observed within the 
pancreatic epithelium after disruption of primary cilium (52), a cellular organelle that is 
intimately associated with Hh-Gli signal transduction (53). Interestingly, another recent 
study showed that Kras-mediated transformation of the pancreatic duct epithelium 
correlates the loss of this organelle in PanIN and PDAC cells in vivo (54).  Thus, Kras 
activation may lead to loss of the primary cilium, which could potentially facilitate the Hh 
ligand-independent activation of Gli activity in tumor epithelium. 
 
Gli1 activation in pancreatic cancer  
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Our results on the cooperation of Gli1 with Kras provided the first evidence for the in 
vivo tumorigenic potential of Gli1 in the pancreas. However, it is interesting to note the 
phenotypic differences between Gli1 and Gli2 activation in pancreatic tumor initiation. 
Whereas Gli1 is unable to initiate pancreatic tumorigenesis on its own, activation of Gli2 
by the CLEG2 allele drives pancreatic neoplasia, albeit the development of 
undifferentiated tumors that do not progress via PanINs (14). Several possibilities may 
account for the difference. First, there are differences in the design of the transgenes. 
The R26-Gli1 allele (30) allows Cre-dependent expression of the full-length Gli1 protein 
from the ubiquitously expressed Rosa26 locus, whereas in the CLEG2 allele (14), a 
dominant active version of Gli2, Gli2∆N, is expressed via control of the CAGGS 
promoter, a highly active hybrid CMV/-actin promoter. Furthermore, Gli2∆N consists of 
an N-terminally truncated form of the protein that lacks an N-terminal repressor domain, 
which may result in resistance to posttranslational regulation (55). Second, different Cre 
drivers were used in these two studies. Compared to Ptf1a-Cre  (26), the Pdx1-Cre 
transgene (56) used in the Gli2∆N study  directs Cre expression in earlier embryonic 
pancreatic progenitor cells. However, it is possible that the phenotypic difference may 
indeed reflect distinct properties of these two Gli proteins; indeed, differential 
transcriptional outputs mediated by Gli1 and Gli2 have been reported (57).  
However, in the context of Kras-initiated pancreatic tumorigenesis, both Gli1 and Gli2 
showed remarkable capacity to accelerate tumor development. Ectopic expression of 
either Gli1 or Gli2∆N, together with Kras activation, resulted in the formation of 
advanced PanIN lesions by 2 months of age. Only minimal early PanIN1A lesions are 
detected at this age in mice with Kras activation alone. Extensive fibrosis was also  
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evident in both Gli1/Kras and Gli2∆N/Kras tumors, a feature similar to desmoplasia 
observed in human PDAC. Despite the frequent formation of advanced lesions at an 
early age, we did not observe invasive or metastatic PDAC in the Ptf1a-Cre;LSL-
Kras
G12D;R26-Gli1 mice that survived to 10 months of age, suggesting the requirement 
for additional oncogenic alterations, possibly loss of p53 or p16 function (6, 7). Another 
intriguing possibility is that paracrine signaling of Hh ligands to the reactive stroma is 
involved in the stimulation of metastasis. It would be interesting to test whether Gli 
activation, together with Hh ligand up-regulation in postnatal mouse pancreas, may lead 
to the development of metastatic PDAC.  
 
A unique Gli transcriptional program in PDAC 
Despite the importance of Kras in PDAC, the transcriptional output regulated by this 
signaling in pancreatic cancer cells remains poorly characterized. Our data here, in 
agreement with prior studies, place Gli transcription factors downstream of Kras in 
pancreatic cancer, and our gene expression profiling studies potentially describe a non-
canonical transcriptional regulation controlled by Gli proteins in PDAC cells. 
Interestingly, we did not detect down-regulation of typical Hh-Gli mitogenic targets, such 
as cyclin D1 and MYC that are commonly found in Hh-related tumors (58-60). Although 
we can not rule out the possibility that Gli3T inhibition may not fully recapitulate the 
Gli1/2 null phenotypes in PDAC cells, our data support the idea that Gli proteins may 
exert a unique transcriptional program in pancreatic cancer cells, a notion that is 
consistent with recent studies that Gli-mediated transcriptional output is highly context 
dependent (25, 31, 61). Our data also suggest that canonical Wnt signaling is unlikely to  
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play a major role in Gli-dependent pancreatic epithelial transformation. Instead, we 
identified a cluster of Gli-dependent genes that are possibly involved in selective 
feedback regulation of Kras-stimulated signal transduction in PDAC cells. Further, our 
finding that Gli3T expression in Panc1 cells suppresses Akt phosphorylation, and that 
Gli activity is required for the elevated expression of the PI3K subunits PIK3R1 and 
PIK3C2B in these cells, supports the intriguing possibility that Gli proteins may directly, 
or indirectly, contribute to the selective activation of the PI3K/AKT pathway.    
 
IKBKE and NF-B activation in pancreatic cancer 
NF-B activity has long been linked to inflammation-related tumorigenesis  (62-64). 
There is also increasing recognition of intrinsic dysregulation of the pathway in solid 
tumors. Alteration of NF-B pathway components was a common finding in a recent 
comprehensive genomic screen of somatic copy-number alterations across human 
cancers (65). Further, activation of the NF-B pathway, possibly via non-canonical IKK 
kinases such as IKBKE and TBK1, has recently been shown to be critical for several 
epithelial tumors, including breast and lung carcinomas that harbor KRAS mutations 
(42, 43, 66, 67). Our results in human PDAC cells and mouse tumors indicate enhanced 
NF-B activity in the tumor epithelium, a finding that is consistent with previous studies 
on NF-B activation in human PDAC cells (68, 69). Our data further suggest that the 
IKK-related kinase, IKBKE, may play an important functional role in PDAC downstream 
of Gli proteins. IKBKE levels are elevated in pancreatic tumors with concomitant 
expression of activated Kras and Gli1, and IKBKE knockdown impairs the survival and 
transformation of PDAC cells.  IKBKE was recently identified as a breast cancer  
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oncogene (43), and recent work demonstrated elevated levels in PDAC samples(44). 
Therefore, it will be interesting to test whether IKBKE functions as an oncogene in 
PDAC as well.  Our finding that multiple components of the NF-B pathway are 
regulated downstream of Gli3T also suggest a potential link between Kras activation 
and NF-B mediated, in part, by Gli transcription factors. Interestingly, while our data 
show a novel cell-autonomous regulation of IKBKE/NF-B by Gli, a recent report 
suggested that Shh ligand production may be regulated by NF-B activity in PDAC cells 
(70). Clearly, further in vivo studies are warranted to elucidate the mechanism of, and 
requirement for, the interplay among these critical pathways in the pathogenesis of 
pancreatic cancer.  
 
MATERIALS AND METHODS  
Mouse strains: Ptf1a-Cre, LSL-Kras
G12D, Trp53
flox, R26-Gli3T and R26-Gli1 mice have 
been described before  (25-28, 31). Ptf1a-Cre;LSL-Kras
G12D, Ptf1a-Cre;LSL-
Kras
G12D;R26-Gli3T, and Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1 mice were obtained by 
crossing  LSL-Kras
G12D to Ptf1a-Cre;R26-Gli3T or Ptf1a-Cre;R26-Gli1 mice. Offspring 
from the cross of LSL-Kras
G12D;R26-Gli3T  to Ptf1a-cre;Trp53
flox/flox mice were followed 
longitudinally for tumor development for 270 days.  All mouse experiments were 
performed according to the guidelines of IACUC at University of Massachusetts Medical 
School.  
Tissue collection and histology: Upon euthanasia, primary pancreatic tissues and 
metastatic lesions were separated in pieces and fixed in 4% paraformaldehyde. For  
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paraffin sections, tissues were dehydrated, and embedded in paraffin blocks, and cut at 
a thickness of 6 μm. For frozen sections, tissues were dehydrated in 30% sucrose, and 
embedded in OCT, and sections were cut at a thickness of 12 μm. For RNA and protein 
analysis, tissues were flash frozen in liquid nitrogen. Tissue sections (6 μm) were 
stained with hematoxylin and eosin (H&E) using standard reagents and protocols. 
Generation of cell lines from tumor tissue: Pancreatic tumors were dissected, 
minced, and digested at 37°C in a Hank’s balanced salt solution (HBSS) containing 2 
mg/mL type V collagenase (Sigma) with agitation. After 20 minutes, the digested 
material was filtered through a 105-μm nylon mesh, and proteases were inactivated by 
the addition of DMEM/F12 (Invitrogen) supplemented with 10% fetal bovine serum. The 
tissue was then washed 3 times in HBSS to remove collagenase. The ductal fragments 
were plated on plastic dishes precoated with rat tail collagen type 1 (BD Bioscience) for 
further growth in monolayer. 
Immunohistochemistry, immunefluorescence and immunoblotting: For 
immunohistochemistry, high-temperature antigen retrieval was conducted in Sodium 
Citrate solution (pH 6.0) on paraffin sections for 30 minutes. Sections were blocked in a 
buffer containing 5% BSA and 0.1% Triton X-100 in PBS and then incubated overnight 
at 4
0 C in primary antibodies diluted in blocking buffer. Primary antibodies used were: 
Ki67 (1:500, Abcam), phospho-AKT (1:50, Cell Signaling), phospho-ERK (1:500, Cell 
Signaling), IKBKE (1:50, Santa Cruz), RelA (1:50, Santa Cruz), β-Catenin (1:400, BD 
Transduction), Estrogen receptor (1:1000, Santa Cruz), Progesterone receptor (1:1000, 
Santa Cruz) and PDX1 (1:5000, gift of Dr. Chris Wright, Vanderbilt University). Signal  
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detection was accomplished with biotinylated secondary antibodies in the Vectastain 
ABC kit (Vector Labs).  
For immunofluorescence, OCT sections were washed with PBS and incubated in 
blocking buffer containing 5% sheep serum, 1% FBS and 0.1% Triton X-100 in PBS. 
Sections were then incubated overnight at 4
0 C in primary antibodies diluted in blocking 
buffer. Primary antibodies used were: Glucagon (1:3000, gift of Dr. Andrew Leiter, 
UMMS), Amylase (1:800, Sigma), Insulin (1:100, Abcam), Smooth muscle actin (1:500, 
Sigma), Cytokeratin-8 (1:100, DSHB). Alexa-Fluor fluorescent conjugated secondary 
antibodies (Invitrogen) were used for detection at a concentration of 1:500 diluted in 
blocking buffer. Slides were then mounted in mounting media containing DAPI.   
For immunoblotting, primary antibodies used were: FlagM2-HRP (1:1000, Sigma), β-
Actin (1:1000, Sigma), phospho-AKT (1:1000, Cell Signalling), phospho-ERK (1:1000, 
Cell Signaling), AKT (1:1000, Cell Signaling), ERK (1:1000, Cell Signaling), IKBKE 
(1:1000, Sigma), and Myc (1:1000, DSHB). HRP conjugated secondary antibodies used 
for detection were obtained from Jackson Laboratories. 
Alcian blue staining and senescence-associated β-galactosidase staining: For 
Alcian blue staining, paraffin sections were hydrated and stained for 30 minutes at room 
temperature using Alcian blue reagent (IHC World). Sections were counterstained with 
Nuclear Fast Red. For senescence associated β-galactosidase staining, frozen sections 
were washed in PBS and stained overnight using Senescence β-galactosidase staining 
solution (Cell Signaling Technology). Sections were counterstained using eosin.  
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Cell proliferation, apoptosis and soft-agar assays: Gli3T-expressing GFP positive 
Panc1 or MiaPaCa2 cells were isolated 24 hours after transfection using flow cytometry. 
For shRNA knockdown, Panc-1 or MiaPaca2 cells were infected with pLKO based 
lentiviruses expressing shRNAs, and selected for 4 days using puromycin. For GANT61 
inhibition, Panc-1 or MiaPaca2 cells were treated with 5 µM or 10 µM GANT61 
dissolved in DMSO.  
For MTT-based cell proliferation assay, the cells were seeded at a density of 3000 per 
well in a 96-well plate, treated with 5 mg/ml MTT 5 days after seeding, and lysed in 
DMSO 4 hours later. Absorbance was measured at 595 nm. Assay was performed in 
triplicates, and standard deviation was used to calculate error bars. 
For apoptosis assay, cells were plated in chamber slides after cell sorting, drug 
selection, or GANT61 treatment. Cells were fixed in 4% PFA. Immunostaining with a 
polyclonal antibody against cleaved caspase 3 (1:400, Cell Signaling) was used as a 
marker for apoptosis. Apoptotic cells were counted in three wells, and relative apoptosis 
was measured by comparing number of apoptotic cells with control sample. Standard 
deviation was used to calculate error bars. 
For anchorage-independent growth assay using soft-agar, cells were seeded at a 
density of 6000 cells/well in a 6-well plate of 0.3% agarose in DMEM media containing 
10% FBS. Colonies from 12 fields of view were counted 14 days later. Assays were 
performed in triplicate. Error bars were calculated using standard deviation between 
triplicates.  
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Luciferase reporter analysis: NIH3T3 or Panc1 cells were co-transfected with 
luciferase reporter constructs, GliBS-Luc (gift of Dr. H. Kondoh, Osaka University), 
TOPflash (Addgene), SRE-luc (gift of Dr. D. Wu, Yale University), NF-κB-Luc (gift of Dr. 
F. Chan, UMMS), and expression vectors for Renila luciferase, Gli3T, Gli1, Gli2, Lef1 
and CDC42. For Gli1 knockdown, the cells were co-transfected with shRNAs targeting 
Gli1 along with NF-kB luciferase, and Renila expression plasmids. For GANT61 
treatment, the Panc-1 cells were co-transfected with NF-kB reporter, and Renila 
Luciferase, and then treated with 5 µM or 10 µM GANT61 6 hours post transfection. 
Luciferase assays were conducted  48 hours after transfection using the dual-luciferase 
reporter kit (Promega). Assays were conducted in triplicates, and standard deviation 
was used to calculate error bars. 
Detection of recombination at the R26-Gli3T locus: Polymerase chain reaction was 
performed on isolated genomic DNA using the primer pair (Forward: 5’- 
GTAGTCCAGGGTTTCCTTGATG-3’, Reverse: 5’-TGCTACTTCCATTTGTCACGTC-3’) 
for detection of the unrecombined R26-Gli3T allele, and (Forward: 5’-
GTAGTCCAGGGTTTCCTTGATG-3’, Reverse: 5’-GGACTTTCATCCTCATTGGAAG-3’) 
for detection of the recombined allele. Primers to the native R26 locus were used as a 
control (Forward: 5’-GGAGCGGGAGAAATGGATATG-3’, Reverse: 5’- 
AAAGTCGCTCTGAGTTGTTAT-3’) 
Quantitative RT-PCR: cDNA synthesis was conducted using Invitrogen Superscript II 
kit. Primers used for quantitative RT-PCR were:  human IKBKE (Forward: 5’-
TGCGTGCAGAAGTATCAAGC-3’; Reverse: 5’-TACAGGCAGCCACAGAACAG-3’), 
mouse IKBKE (Forward: 5’- GCGGAGGCTGAATCACCAG-3’; Reverse: 5’- 
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GAAAGCCCGAACGTGTTCTCA-3’), Axin2 (Forward: 5’- 
AGTGTGAGGTCCACGGAAAC -3’; Reverse: 5'- CTTCACACTGCGATGCATTT-3'), 
human GAPDH (Forward: 5’-ATGGGGAAGGTGAAGGTCG-3’; Reverse: 5’-
GGGGTCATTGATGGCAACAATA-3’),  mouse GAPDH (Forward: 5’-
AGGCCGGTGCTGAGTATGTC-3’; Reverse: 5’-TGCCTGCTTCACCACCTTCT-3’), β-
actin  (Forward: 5’- TGACAGGATGCAGAAGGAGA-3’; Reverse: 5’-
CTGGAAGGTGGACAGTGAGG-3’), human Gli1 (Forward: 5’ 
CCAGCGCCCAGACAGAG-3’;Reverse:5’-GGCTCGCCATAGCTACTGAT-3’), mouse 
Gli1 (Forward: 5’- GTCGGAAGTCCTATTCACGC-3’;Reverse: 5’-
CAGTCTGCTCTCTTCCCTGC-3’), human Patched-1 (Forward: 5’-
CCACAGAAGCGCTCCTACA-3’;5’-CTGTAATTTCGCCCCTTCC-3’) and mouse 
Patched-1 (Forward: 5’-AACAAAAATTCAACCAAACCTC-3’;Reverse: 5’-
TGTCTTCATTCCAGTTGATGTG-3’). All qPCR assays were conducted in triplicates, 
and standard deviation was used to calculate error bars. 
Gli1 and IKBKE knockdown:  Panc1 or MiaPaCa2 cells were infected with pLKO-
based lentiviruses encoding shRNAs targeting human Gli1 (shGli1#1: 
CATCCATCACAGATCGCATTT; shGli1#2: GCTCAGCTTGTGTGTAATTAT), and 
human  IKBKE  (shIKBKE#1: TGGGCAGGAGCTAATGTTTCG; shIKBKE#2: 
GAGCATTGGAGTGACCTTGTA). Infected cells were selected in 5 μg/ml puromycin for 
4 days. MTT assay, soft agar assay, and Caspase staining for apoptosis were 
conducted as described previously.  
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PDEC proliferation and survival: PDECs from Keratin19-tv-a;R26-Gli3T  double 
transgenic mice were isolated and cultured as previously described (15). The retroviral 
constructs  RCAS-GFP  and  RCAS-KrasG12D-IRES-GFP  (15) have been previously 
described. RCAS-Cre was a gift from Eric Holland (Memorial Sloan-Kettering Cancer 
Center). Isolated PDECs were infected with either RCAS-KrasG12D-IRES-GFP  or 
RCASGFP, and subsequently infected with RCAS-Cre to induce Gli3T expression, or 
with RCAS-GFP as a control. Cell proliferation and survival assays were performed as 
previously described (15). 
 
Affymetrix gene chip analysis: Panc-1 cells were transfected with a GFP expressing 
vector carrying Gli3T (pCIG-Gli3T) or a GFP expressing empty vector (pCIG). GFP 
positive cells were isolated 24 hours post transfection using flow cytometry. RNA was 
isolated, labeled and hybridized to mouse GeneST1.0 chips (Affymetrix) according to 
Affymetrix protocols. Three independent biological samples were used for chip analysis. 
Statistical analyses were performed using R, a system for statistical computation and 
graphics (http://www.r-project.org). Genes with adjusted p-value <0.05 and absolute fold 
change ≥1.5 were considered potential targets for further investigation. 
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FIGURE LEGENDS 
Figure 1. Gli-induced transcriptional activation is dispensable for pancreatic 
development.  (A-C) Gli3T blocks Gli-dependent transcriptional activity. Gli3T inhibits 
Gli-mediated luciferase reporter activity induced by Gli1 and Gli2 in transfected NIH3T3 
cells (A). Gli3T does not inhibit TCF4-induced TopFlash reporter activity (B), or serum 
response factor-dependent SRE-luciferase reporter activity induced by the CDC42 
GTPase (C). Open bars: control cells; black bars: Gli3T-expressing cells. (D) 
Immunoblot detection of Gli3T
 expression in pancreatic lysates from 6-month-old R26-
Gli3T and Ptf1a-Cre;R26-Gli3T mice using an antibody against  the Flag epitope tag. 
(E-N) H&E staining (E and J), immunofluoresence staining of amylase (F and K), 
glucagon (G and L) and insulin (H and M), and Venus fluorescence (I and N) in 
pancreata derived from R26-Gli3T (E-I) and Ptf1a-Cre;R26-Gli3T (J-N) mice.  
 
Figure 2. Gli-mediated transcription is required for Kras-initiated PanIN formation. 
(A-F) Representative histological sections from Ptf1a-Cre;LSL-Kras
G12D  (A, C and E) 
and Ptf1a-Cre;LSL-Kras
G12D;R26-Gli3T (B, D and F) mice stained with H&E (A and B), 
Alcian blue (C and D) and an antibody against Ki67 (E and F). (G-J) PanIN lesions 
detected in Ptf1a-Cre;LSL-Kras
G12D;R26-Gli3T  mice. H&E staining shows wide-spread 
advanced PanIN formation in Ptf1a-Cre;LSL-Kras
G12D pancreata (G), while only rare 
PanIN1 lesions were detected in a 12-month-old Ptf1a-Cre;LSL-KRAS
G12D;R26-Gli3T 
mouse (H, I). Note robust Venus fluorescence in adjacent acinar and endocrine cells  
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indicating expression of Gli3T. The boundary of the lesions from the adjacent slides is 
delineated by dashed black (I) and white (J) lines.  
 
Figure 3. Gli transcriptional activation is required for PDAC formation. (A) Kaplan-
Meier survival curve for Ptf1a-Cre;LSL-Kras
G12D;Trp53
flox/wt mice, Ptf1a-Cre;LSL-
Kras
G12D;Trp53
flox/wt;R26-Gli3T mice, and Ptf1a-Cre- and LSL-Kras
G12D-negative 
littermate controls. p < 0.001 for comparison between R26-Gli3T-positive and –negative 
animals. (B) Representative H&E stained histological sections from lesions arising in 
Ptf1a-Cre;LSL-Kras
G12D;Trp53
flox/wt  (i-v) and Ptf1a-Cre;LSL-Kras
G12D;Trp53
flox/wt;R26-
Gli3T mice (vi-ix). PanIN lesions (i), glandular PDAC (ii), undifferentiated carcinoma (iii), 
lymph node metastasis (iv), and liver metastasis identified in Ptf1a-Cre;LSL-
Kras
G12D;Trp53
flox/wt mice. Glandular PDAC (vi), undifferentiated carcinoma (vii), liver 
metastasis (viii) and intestinal invasion (ix) observed in Ptf1a-Cre;LSL-
Kras
G12D;Trp53
flox/wt;R26-Gli3T mice. (C) Immunoblotting for Gli3T protein (using an anti-
Flag antibody) in lysates from R26-Gli3T-positive and -negative tumors (top panel) and 
cell lines derived from these tumors (bottom panel). (D) PCR of genomic DNA to detect 
the recombination status of the R26-Gli3T allele in R26-Gli3T-positive tumor samples. 
Amplification of the native Rosa26 locus was used as a control. 
 
Figure 4. Gli1 promotes Kras-initiated pancreatic tumorigenesis.  (A) Survival of 
Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1 mice is significantly less than that of Ptf1a-Cre;LSL-
Kras
G12D and Ptf1a-Cre;R26-Gli mice.  (B-D) H&E staining of panceata derived from 2- 
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month-old  Ptf1a-Cre;R26-Gli1 (B), Ptf1a-Cre;LSL-Kras
G12D (C) and Ptf1a-Cre;LSL-
Kras
G12D;R26-Gli1 (D) mice.  (E) Immunostaining for cytokeratin 8 (red) and -smooth 
muscle actin (green) in a Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1 derived pancreatic lesion. (F 
and G) IHC for Ki67 in Ptf1a-Cre;LSL-Kras
G12D (F) and Ptf1a-Cre;LSL-Kras
G12D;R26-
Gli1 (G) pancreata. (H and I) Senescence-associated β-galactosidase staining of 
pancreatic lesions from Ptf1a-Cre;LSL-Kras
G12D (H) and Ptf1a-Cre;LSL-Kras
G12D;R26-
Gli1 (I) mice. (J) H&E staining of pancreatic cystic lesions from a 1-month-old Ptf1a-
Cre;LSL-Kras
G12D;R26-Gli1 mouse. (K) Alcian blue staining revealing abundant mucin 
production in epithelial cells in the cysts.  
 
Figure 5. Gli-mediated transcriptional program in pancreatic cancer cells. ( A) 
Changes in Gli-luciferase reporter activity in Gli3T-expressing and control Panc1 (black 
bars) and MiaPaCa2 (gray bars) cells. (B) Cell proliferation, measured by MTT assay, 
(C) apoptosis, and (D) anchorage-independent soft agar colony formation by FACS-
isolated Gli3T-expressing and control Panc1 (black bars) and MiaPaCa2 (gray bars) 
cells. (E) Heat map illustrating mRNA expression of selected genes in Gli3T-expressing 
and control Panc1 cells. Red, high expression; green, low expression.  (F) Immunoblot 
analysis of the levels of AKT phosphorylation (p-AKT), total AKT, ERK phosphorylation 
(p-ERK), and total ERK, in isolated Gli3T-expressing and control Panc1 cells. (G-J) IHC 
for p-AKT (G and H) and p-ERK (I and J) in pancreatic lesions from Ptf1a-Cre;LSL-
Kras
G12D (G and I) and Ptf1a-Cre;LSL-Kras
G12D;R26-Gli1 (H and J) mice at 2 months of 
age.   
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Figure 6. Gli regulates IKBKE and NF-B activity in pancreatic cancer cells. (A) 
Inhibition of NF-B reporter activity by Gli3T, shRNAs against Gli1, and GANT61 in 
Panc1 cells 48 hours after transfection.  (B) qPCR analysis of IKBKE mRNA expression 
in response to Gli3T expression, Gli1 knockdown, and GANT61 treatment. (C) 
Immunoblot analysis of IKBKE expression in control and Gli3T-expressing Panc1 cells.  
(D) qPCR analysis of IKBKE mRNA level in Panc1 cells expressing shRNA constructs 
against GFP (control) or IKBKE (shIKBKE #1 and shIKBKE #2). (E) Immunoblot 
analysis for expression of myc-tagged mouse IKBKE (mIKBKE) in Panc1 cells 
expressing shRNA constructs against human IKBKE.  Cell proliferation (F), apoptosis 
(G) and soft agar colony formation (H) in Panc1 cells expressing shRNA constructs 
against GFP or IKBKE with or without mouse IKBKE expression. IHC staining of IKBKE 
(I, J) and RelA (K,L) in pancreatic lesions from Ptf1a-Cre;LSL-Kras
G12D (I,K) and Ptf1a-
Cre;LSL-Kras
G12D;R26-Gli1 (J, L) mice. Note the predominantly cytoplasmic staining of 
RelA in panel J, and increased nuclear staining in panel K.  
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